11 |
Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin /James, Stefan, January 2003 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 4 uppsatser.
|
12 |
Calcium regulation in coronary smooth muscle : mechanisms of cardioprotection /Wamhoff, Brian R., January 2001 (has links)
Thesis (Ph. D.)--University of Missouri--Columbia, 2001. / "May 2001." Typescript. Vita. Includes bibliographical references (leaves 176-195). Also available on the Internet.
|
13 |
Chemoattractants as causative agents, biomarkers and therapeutic targets in vascular pathology /Sheikine, Yuri, January 2006 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.
|
14 |
Pharmacogenomics and genetic risk factors of coronary artery diseaseDuan, Qingling. January 2008 (has links)
Coronary artery disease (CAD) is the most prevalent disorder and the leading cause of death worldwide. There are a number of CAD medications, which are effective and safe in most patients, but have been associated with adverse reactions such as angioedema induced by angiotensin I-converting enzyme inhibitors (AE-ACEi). In this study, we identified aminopeptidase P (APP) activity as an endophenotype for AE-ACEi, which is a heritable quantitative trait (heritability =0.336 +/- 0.251 SD) and is significantly reduced in a majority of our cases. Although initial mutation screening did not reveal any coding variants in XPNPEP2, which encodes membrane-bound APP, subsequent linkage analysis of APP activity in eight families provided a maximum LOD score (3.75) for this locus. Sequencing of additional cases identified a splice variant (314_431del) and a non-coding polymorphism (rs3788853) in this locus, which cosegregate with low plasma APP activity. The latter accounts for the linkage signal and is associated with AE-ACEi (P = 0.036). In addition, we identified other potential loci for APP activity and demonstrated that certain ACEi (Captopril and Enalapril) non-specifically inhibit APP activity. Furthermore, we detected polymorphisms associated with reduced APP and ACE activities among females with estrogen-dependent inherited angioedema. / We also conducted a genetic investigation of depression among CAD patients to identify common susceptibility loci which might explain the correlation between these diseases. Our candidate gene association study identified a polymorphism (rs216873) in the von Willebrand factor gene that was significantly associated (P = 7.4 x 10-5) with elevated depressive symptoms in our CAD cohort. These results suggest that risk factors for atherosclerosis also underlie susceptibility to depression among CAD patients. / This dissertation contributes to the field of genetics and pharmacogenomics of CAD. A better understanding of the toxic effects of CAD drugs will assist in the development of safer and more effective treatments. In addition, our results may facilitate clinical assays to identify individuals who are susceptible to angioedema prior to ACEi or estrogen therapy. Finally, our genetic investigation of depression in CAD patients reveals a novel drug target (VWF) for treatment of depression in cardiac cases.
|
15 |
Studies on cell injury induced by hypoxia-reoxygenation and oxidized low density lipoprotein : with special reference to the protectiove effect of mixed tocopherols, omega-3 fatty acids and transforming growth factor-beta1 /Chen, Hongjiang, January 2003 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 5 uppsatser.
|
16 |
The immune response in atherosclerosis and acute coronary syndromes /Caligiuri, Giuseppina, January 1900 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst. / Härtill 5 uppsatser.
|
17 |
Inflammation and matrix degrading proteases in coronary artery disease /Samnegård, Ann, January 2006 (has links)
Diss. (sammanfattning) Stockholm : Karol. inst., 2006. / Härtill 4 uppsatser.
|
18 |
Cardiac exercise studies with bioelectromagnetic mappingTakala, Panu. January 2001 (has links) (PDF)
Thesis (Ph. D.)--Helsinky Univ. of Technology, 2001. / Title from title screen (viewed Oct. 14, 2005). Includes bibliographical references.
|
19 |
Evaluating reasons for practice variation in the management of secondary prevention measures among coronary artery disease patients /Ho, P. Michael. January 2005 (has links)
Thesis (Ph.D. in Clinical Sciences) -- University of Colorado at Denver and Health Sciences Center, 2005. / Typescript. Includes bibliographical references (leaves 100-112). Free to UCDHSC affiliates. Online version available via ProQuest Digital Dissertations;
|
20 |
Pharmacogenomics and genetic risk factors of coronary artery diseaseDuan, Qingling. January 2008 (has links)
No description available.
|
Page generated in 0.1137 seconds